- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02570113
The Peregrine Post-Market Study for the Treatment of Hypertension
A Post-Market Study of Transcatheter Perivascular Renal Denervation for the Treatment of Hypertension Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is strong evidence in the published literature that the renal nerves are important contributors to hypertension, and that their ablation does not have adverse side-effects.
The literature provides technical, clinical and scientific evidence supporting the use of perivascular renal denervation for a carefully defined patient group.
An existing device (the Medtronic Symplicity catheter) was initially shown to be safe and effective for achieving perivascular renal denervation by delivery of radio-frequency energy. The results of early nonrandomized clinical studies (HTN-1, HTN-2) found that perivascular renal denervation by radio-frequency energy delivery was an effective therapy, associated with very low risks. In other contexts, denervation can also be safely and effectively achieved by neurolytic agents.
The ASI Peregrine System™ Infusion Catheter and the denervation procedure in general is similar enough to the Medtronic Symplicity catheter to enable the use of published data to establish the validity of the design concept of the Peregrine System and estimate the likely levels of risk of side effects. It can be concluded from the literature that the ASI Peregrine System™ will achieve percutaneous renal denervation with a low risk of procedural complications (comparable to accepted percutaneous interventional therapies) and without long-term impairment of renal artery or kidney function or other serious adverse events.
Previous premarket clinical trials have provided support for the safe and effective use of the Peregrine Catheter for the treatment of patients with hypertension. The Peregrine System Infusion Catheter is currently CE marked and the indication for use is "The Peregrine System™ Infusion Catheter is intended for the infusion of a neurolytic agent to achieve a reduction in systemic blood pressure in hypertensive patients." Based upon the literature and previous clinical data, chemical denervation is an appropriate treatment for the specified study population of adults who have hypertension despite taking at least 3 anti-hypertensive drugs of different classes including at least one diuretic.
The objectives of this post-market study are to collect additional safety and performance data pertaining to renal denervation by using dehydrated alcohol as a chemical neurolytic agent delivered into the adventitial/peri-adventitial area of the renal arteries for the purpose of renal denervation, using the Peregrine System™ Infusion Catheter, in patients with hypertension.
In order for the study to be valid, only one chemical neurolytic agent can be used. The Coordinating Investigator has chosen to use dehydrated alcohol (not less than 95% by volume) for therapeutic neurolysis, therefore all participating sites will use this agent.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1200
- Cliniques Universitaires Saint-Luc
-
-
-
-
-
Prague, Czechia, 150 30
- Na Homolce Hospital
-
-
-
-
-
Berlin, Germany, 12203
- Charite-Universitaetsmedizin Berlin
-
Erlangen, Germany, 91054
- Universitätsklinik Erlangen Klinik für Nephrologie/Hypertensiologie
-
Essen, Germany, 45138
- Elisabeth-Krankenhause
-
Frankfurt, Germany, 60389
- CardioVasculares Centrum (CVC) Frankfurt
-
Freiburg, Germany, 79106
- Universitats-Herzzentrum/University Heart Center Klinik fur Kardiologie und Angiologie
-
Homburg, Germany, 66421
- Klinik fur Innere Medizin III
-
-
-
-
-
Tychy, Poland, 43-100
- Oddzial Kardiologii Inwazyjnej
-
Ustron, Poland, 43-450
- Oddizal Kardiologiczno-Angiologiczny PAKS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult subject, age 18-80, male or female;
- Subject has a target treatment vasculature diameter of ≥4 mm and ≤ 7 mm and length of ≥5 mm;
Subject has 3 measurements with a mean of office Systolic Blood Pressure of
≥150 mmHg AND office Diastolic Blood Pressure of ≥85 mmHg;
- Subject has a 24-hour mean systolic Ambulatory Blood Pressure Measurement (ABPM) ≥135 mm Hg with ≥70% valid readings (as determined by measurement device);
- Subject with hypertension is receiving and adhering to a stable medication regimen of at least 3 anti-hypertensive medications of different classes (for at least 4 consecutive weeks), one of which must be a diuretic;
- Subject agrees to have all study procedures performed, to comply with medication regimen and is able and willing to comply with all study follow-up visits;
- Subject has provided written informed consent.
Exclusion Criteria:
Subject has a contraindication known for conventional percutaneous interventional procedures such as:
- intolerance for antiplatelet/anticoagulant therapy
- known allergy to contrast media
- bleeding disorders (such as bleeding diathesis, thrombocytopenia and severe anemia)
- Subject has documented severe untreated obstructive sleep apnea (Apnea Hypopnea Index [AHI] ≥30 per hour);
- Subjects with nephrotic syndrome;
- Subjects on immunosuppressive medications or immunosuppressive doses of steroids;
- Subject has type 1 diabetes mellitus;
- Subject is pregnant or nursing or planning to become pregnant;
Subject has an eGFR ≤20 mL/min/1.73m2
, based on the CKD-EPI equation;
Subject has imaging-assessed renal artery anatomy abnormalities or variations based on Investigator's evaluation of the screening images [i.e. MRA/CTA examination and/or renal angiography]) meeting one of the following criteria:
- Renal artery stenosis >60% of the normal diameter segment (diameter stenosis, compared to the angiographically normal proximal or distal segment);
- Any renal artery abnormality or disease that, per the physician assessment, precludes the safe insertion of the guiding catheter (such as but not limited to severe renal artery aneurysm, excessive tortuosity, severe renal artery calcification);
- Previous renal angioplasty associated with stenting or other implants, that, per the physician's assessment, precludes the safe deployment of the Peregrine catheter components in the target treatment segment of the renal artery;
- Subject has a history of nephrectomy, a single kidney or kidney tumor, or urinary tract obstruction (with potential for hydronephrosis);
- Subject is known to have a non-functioning kidney or unequal renal size (>2 cm difference in renal length between kidneys associated with a chronic kidney disease or a deterioration of the kidney function);
- Subject has a renal transplant;
- Subject has a history of myocardial infarction, unstable angina pectoris, or stroke/TIA within the last six months from planned procedure;
- Subject has hemodynamically significant valvular heart disease;
- Subject has heart failure (NYHA III or IV) or has an ejection fraction ≤30%;
- Subject with chronic atrial fibrillation;
- Subjects who are allergic or intolerant of the neurolytic agent (such as dehydrated alcohol);
- Any contraindication to the imaging as required per the protocol;
- Subject has a life expectancy of <12 months;
- Subject is currently enrolled in other potentially confounding research, i.e., another therapeutic or interventional research trial. Subjects enrolled in observational registries may still be eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Renal Denervation by Neurolysis
Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
|
The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With the Absence of Particular Events as Adjudicated by the CEC Through 1-month Post Procedure:
Time Frame: 1-month
|
The primary safety endpoint is defined by the absence of any of the following events as adjudicated by the CEC through 1-month post procedure:
|
1-month
|
Change in 24-hour Mean Ambulatory Systolic Blood Pressure From Baseline to 6 Months
Time Frame: 6 months
|
The primary performance endpoint is defined as a reduction of 24-hour mean ambulatory systolic blood pressure following treatment at 6 months, as compared to baseline.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in eGFR
Time Frame: 1, 3, 6 and 12 months
|
Change in eGFR from baseline, to evaluate the progression of Chronic Kidney Disease (CKD) after 1, 3, 6 and 12 months;
|
1, 3, 6 and 12 months
|
Numbr of Subjects With a Decline in eGFR by >25% From Baseline to 6 Months
Time Frame: 6 months
|
Proportion of subjects with a decline in eGFR by >25% from baseline to 6-month follow-up;
|
6 months
|
Change in Serum Creatinine From Baseline to 6 Months
Time Frame: 6 months
|
Change in serum creatinine from baseline to 6-month follow-up
|
6 months
|
Number of Participants With New Renal Arterial Stenosis > 60%
Time Frame: 6 months
|
Number of Participants with New renal arterial stenosis > 60% from the baseline at the 6-month follow-up, to be confirmed by the same imaging method used at baseline.
|
6 months
|
Number of Subjects With Stroke or Transient Ischemic Attack (TIA) With 1 Month of the Procedure
Time Frame: 1 month
|
Stroke or TIA within 1 month of the procedure
|
1 month
|
Number of Subjects With Myocardial Infarction (MI) Within 1 Month of the Procedure
Time Frame: 1 month
|
Myocardial Infarction (MI) within 1 month of the procedure
|
1 month
|
Number of Participants With Major Adverse Events (MAE) Through 6 Months Post-Procedure
Time Frame: 6 months
|
Number of Participants with Major Adverse Events (MAE) through 6-month post-procedure. MAE is defined as the occurrence of any of the following:
|
6 months
|
Changes in Antihypertensive Medications at 7 Days, and 1, 3, 6 and 12 Months Post-Procedure
Time Frame: 7-day, 1, 3, 6 and 12 months
|
Changes in antihypertensive medications at 7-day, 1, 3, 6 and 12 months post procedure;
|
7-day, 1, 3, 6 and 12 months
|
Changes in Systolic and Diastolic Clinic/Office Blood Pressure
Time Frame: 7-day, 1, 3, 6 and 12 months
|
Changes in systolic and diastolic clinic/office blood pressure following treatment compared to baseline, assessed at 7-day, 1, 3, 6 and 12 months post-procedure.
|
7-day, 1, 3, 6 and 12 months
|
Changes in Systolic and Diastolic 24-hour Mean Daytime and Nighttime Ambulatory Blood Pressure
Time Frame: 1, 3, 6 and 12-months
|
Changes in systolic and diastolic 24-hour mean daytime and nighttime ambulatory blood pressure, assessed at 1, 3, 6 and 12-month post-procedure.
|
1, 3, 6 and 12-months
|
Changes in Diastolic 24-hour Mean Ambulatory Blood Pressure
Time Frame: 1, 3, 6 and 12-months
|
Changes in systolic and diastolic 24-hour mean ambulatory blood pressure assessed at 1, 3, 6 and 12-month post-procedure.
|
1, 3, 6 and 12-months
|
Changes in Systolic 24-hour Mean Ambulatory Blood Pressure
Time Frame: 1, 3 and 12 months
|
Changes in systolic 24-hour mean ambulatory blood pressure assessed at 1, 3 and 12 months postprocedure;
|
1, 3 and 12 months
|
The Progression of Kidney Disease
Time Frame: 1, 3, 6, and 12 months
|
The progression of kidney disease in subjects with ≤60 mL/min/1.73m2
will be evaluated by comparing the change in eGFR during the study to the historical loss (reduction) of eGFR during the 3 years prior to renal denervation for each individual subject;
|
1, 3, 6, and 12 months
|
Change in Albuminuria
Time Frame: 3, 6, and 12 months
|
Change in albuminuria from baseline to 3 months post-procedure, with additional assessments at each study time point;
|
3, 6, and 12 months
|
Change in Albuminuria Categorization
Time Frame: 3, 6, and 12 months
|
Change in albuminuria categorization from baseline to 3 months post-procedure, with additional assessments at each study time point;
|
3, 6, and 12 months
|
Change in Serum Creatinine and Cystatin-C
Time Frame: 3, 6, and 12 months
|
Change in serum creatinine and cystatin-C from baseline to 3 months postprocedure, with additional assessments at each study time point.
|
3, 6, and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Horst Sievert, MD, CardioVasculares Centrum (CVC) Frankfurt
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Peregrine System Infusion Catheter
-
Ablative Solutions, Inc.CompletedHypertensionCzechia, Poland
-
Texas Tech University Health Sciences Center, El...Texas Tech University Health Sciences CenterTerminatedAnalgesia in Total Knee ArthroplastyUnited States
-
Wright State UniversitySurefire Medical, Inc.TerminatedHepatocellular Carcinoma
-
Postgraduate Institute of Medical Education and...CompletedPost-operative Analgesia | Upper Gastrointestinal Surgery | Wound Infusion Catheter | Upper Midline IncisionIndia
-
Vinmec Healthcare SystemCompletedQuality of Life | Pain, Postoperative | Opioid UseVietnam
-
Assiut UniversityCompletedAbdominal NeoplasmsEgypt
-
Stanford UniversityCompleted
-
Atrium Medical CorporationCompleted
-
Massachusetts General HospitalTriSalus Life SciencesRecruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Liver CancerUnited States
-
Neurotronic, Inc.Libra MedicalRecruitingHypertension | Diabetes Mellitus, Type 2Panama, Paraguay